FDA push­es can­cer drug de­vel­op­ers to in­clude over­all sur­vival da­ta more fre­quent­ly

For years, the FDA has al­lowed pro­gres­sion-free sur­vival to serve as both a pri­ma­ry and sur­ro­gate end­point to sup­port speedy new can­cer drug ap­provals. But with new class­es of on­col­o­gy drugs com­ing to the fore­front, the agency ap­pears to be in­creas­ing­ly call­ing for more ro­bust over­all sur­vival da­ta that can prove treat­ments help pa­tients live longer.

The ap­par­ent move­ment by the FDA, par­tic­u­lar­ly when the OS da­ta aren’t ma­ture, hasn’t ar­rived in the form of draft guid­ance, but via a con­fer­ence and side com­ments from FDA’s top on­col­o­gy ex­pert. This push for more OS da­ta, on top of PFS da­ta, was raised by No­var­tis CEO Vas Narasimhan last week dur­ing the com­pa­ny’s quar­ter­ly earn­ings call, when he called it “new ter­ri­to­ry” for the agency.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER